Actinium Pharmaceuticals
ATNM · United States
Share price · ATNM
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ATNM's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 18 Nov 2026-20.0%
- 22 Oct 2026+15.9%
Nothing announced by ATNM that day or the session before.
- 19 Oct 2026+16.8%
- 8 Sep 2026+19.4%
Nothing announced by ATNM that day or the session before.
- 13 Aug 2026+17.4%
Nothing announced by ATNM that day or the session before.
- 5 Aug 2026-7.5%
Nothing announced by ATNM that day or the session before.
- 29 May 2026+9.6%
- 22 Apr 2026-7.9%
- 20 Apr 2026+10.8%
Nothing announced by ATNM that day or the session before.
- 15 Apr 2026+14.5%
Nothing announced by ATNM that day or the session before.
Share of unusual movement by asset
For each asset, the share of ATNM's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | CD45Monoclonal antibody | Acute Myeloid Leukemia | |
| Phase 2 | CD33Radiopharmaceutical | Acute Myeloid Leukemia |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2029 (1)
February 2029 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $35M | $5.4M | $37M | —-$5.2M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | — | $4.2M | $42M | $5.5M-$5.9M operating cash flow | report ↗ |
| 2025-Q3 | $0.1M | $4.3M | $54M | $5.1M-$6.3M operating cash flow | report ↗ |
| 2025-Q2 | — | $4.9M | $60M | $6.9M-$5.4M operating cash flow | report ↗ |
| 2025-Q1 | — | $7.7M | $66M | $16M-$7.6M operating cash flow | report ↗ |
| 2024-Q3 | — | $9.8M | $79M | $12M-$12M operating cash flow | report ↗ |
| 2024-Q2 | — | $8.8M | $86M | $11M-$8.0M operating cash flow | report ↗ |
| 2024-Q1 | — | $6.6M | $84M | $8.7M-$7.4M operating cash flow | report ↗ |
| 2023-Q3 | — | $12M | $83M | $13M-$11M operating cash flow | report ↗ |
| 2023-Q2 | — | $11M | $92M | $15M-$14M operating cash flow | report ↗ |
| 2023-Q1 | — | $7.8M | $95M | $11M-$15M operating cash flow | report ↗ |
| 2022-Q3 | $0.1M | $6.8M | $113M | $9.5M-$5.7M operating cash flow | report ↗ |
| 2022-Q2 | $0.1M | $4.7M | $117M | $7.8M$28M operating cash flow | report ↗ |
| 2022-Q1 | $0.9M | $4.4M | $72M | $5.1M-$5.8M operating cash flow | report ↗ |
| 2021-Q3 | $0.2M | $4.7M | $82M | $6.4M-$5.6M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0.1M | $21M | $48M | $8.5M-$25M operating cash flow | report ↗ |
Actinium Pharmaceuticals reported revenue of $0.09M for fiscal year 2025, with no prior-year revenue disclosed. R&D spend was $21.12M, down 29.7% YoY, and cash and equivalents totaled $48.33M. The company reported a net loss of $33.89M, with a quarterly net burn of $33.89M.
The clinical-stage radiopharmaceutical company is advancing a pipeline focused on targeted radiotherapies, including ATNM-400 for solid tumors, Actimab-A for AML/MDS and MDSC-mediated resistance to checkpoint inhibitors, and the conditioning agents Iomab-B and Iomab-ACT. Management highlighted FDA alignment on Phase 2/3 trial designs for Iomab-B and Actimab-A plus CLAG-M, active partnership discussions for the hematology programs, and expected initial data from an Actimab-A basket trial in 2H:2026. A radiopharmaceutical manufacturing facility is expected to be commissioned in 2H:2026.
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-14 | David Matthew T · Chief Financial Officer | Award / grant | 250,000 | — | — | Form 4 |
| 2026-10-14 | David Matthew T · Chief Financial Officer | Award / grant (derivative) | 250,000 | — | — | Form 4 |
| 2026-09-02 | Chell Jeffrey W. · director | Award / grant | 61,600 | — | — | Form 4 |
| 2026-09-02 | Steinhart Richard I · director | Award / grant | 62,800 | — | — | Form 4 |
| 2026-09-02 | SETH SANDESH · director, Chief Executive Officer | Award / grant | 753,600 | — | — | Form 4 |
| 2026-09-02 | Almenoff June Sherie · director | Award / grant | 18,000 | — | — | Form 4 |
| 2026-09-02 | Nicholson, C. David · director | Award / grant | 62,800 | — | — | Form 4 |
| 2026-09-02 | Shetty Ajit · director | Award / grant | 61,600 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 54 reporting institutions held 5.3M shares ($4.6M, 16.9% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 1,255,516 | $1.2M |
| 2 | MILLENNIUM MANAGEMENT LLC | 564,600 | $562K |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 471,600 | $469K |
| 4 | BlackRock, Inc. | 371,210 | $369K |
| 5 | TWO SIGMA INVESTMENTS, LP | 337,168 | $336K |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 336,073 | $335K |
| 7 | GAGNON SECURITIES LLC | 201,300 | $200K |
| 8 | VANGUARD FIDUCIARY TRUST CO | 160,265 | $159K |
| 9 | STATE STREET CORP | 126,215 | $126K |
| 10 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 123,998 | $123K |
| 11 | Gen-Wealth Partners Inc | 107,111 | $107K |
| 12 | NORTHERN TRUST CORP | 75,855 | $75K |
| 13 | GOLDMAN SACHS GROUP INC | 70,241 | $70K |
| 14 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 40,000 | $40K |
| 15 | TWO SIGMA SECURITIES, LLC | 35,887 | $36K |